Mylan Laboratories (MYL) Receives Tentative FDA Approval for Generic Depakote ER
More News related to ABT
- Arnold & Itkin Announces Lawsuits Over Defective Pain Pumps
- President of Tanzania and the Abbott Fund Dedicate Modern Emergency Medical Department
- Abbott Saving 1 Billion Gallons of Water Annually
- Abbott Completes Acquisition of Evalve, Inc.
- Crucell NV (CRXL) Up On Renewed Takeover Chatter
More News related to MYL
- Mylan (MYL) Gets FDA Ok for Generic Prevacid
- Mylan Receives FDA Approval for Generic Version of Prevacid(R) Through its Subsidiary Matrix Laboratories
- Mylan Labs (MYL) Tops Q3 EPS by 5c, Guides Higher
- Mylan Reports Third Quarter Adjusted Diluted EPS of $0.32
- Trading Radar for 10/29: Exxon (XOM), Motorola (MOT), Waste Management (WM) Report
More News related to FDA
- Kensey Nash (KNSY) Receives FDA Clearance for its First Extracellular Matrix Product, Medeor
- Teva Pharma (TEVA) Gets Final U.S. FDA Approval for Generic Prevacid
- Mylan (MYL) Gets FDA Ok for Generic Prevacid
Mylan Laboratories Inc. (NYSE: MYL) announced that Mylan Pharmaceuticals Inc. has received tentative approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Divalproex Sodium Extended-release (ER) Tablets, 250mg and 500mg strengths.
Divalproex Sodium ER Tablets are the generic version of Abbot Laboratories' (NYSE: ABT) Depakote ER® Tablets, which had U.S. sales of approximately $698 million for the same strengths for the 12-month period ending Dec. 31, 2006, according to IMS Health.
Related Categories
FDAStocks Mentioned
+0.46
-0.07Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
